[关键词]
[摘要]
目的 研究喘嗽宁片联合丙酸氟替卡松吸入气雾剂治疗咳嗽变异性哮喘的临床疗效。方法 选取2017年3月-2019年1月宝鸡市中医院收治的100例咳嗽变异性哮喘患者为研究对象,采用随机对照组法将所有患者随机分为对照组和治疗组,每组各50例。对照组患者雾化吸入丙酸氟替卡松吸入气雾剂,2揿/次,2次/d;治疗组患者在对照组的基础上口服喘嗽宁片,4片/次,3次/d。两组患者持续治疗4周。观察两组的临床疗效,比较两组的肺功能指标、嗜酸性粒细胞(EOS)计数、嗜酸性粒细胞阳离子蛋白(ECP)水平和炎性因子水平。结果 治疗后,对照组和治疗组的总有效率分别为78.00%、92.00%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者用力肺活量(FVC)、第一秒用力呼气容积(FEV1)和FEV1/FVC均明显升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者肺功能指标明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者EOS计数和ECP水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组患者EOS计数和ECP水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平均显著降低,白细胞介素-10(IL-10)水平显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组患者hs-CRP、TNF-α、IL-10水平明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论 喘嗽宁片联合丙酸氟替卡松吸入气雾剂治疗咳嗽变异性哮喘具有较好的临床疗效,能改善肺功能,降低血清炎性因子水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To study the efficacy of Chuansouning Tablets combined with Fluticasone Propionate Inhaled Aerosol in treatment of cough variant asthma. Methods Patients (100 cases) with cough variant asthma in Baoji Hospital of Traditional Chinese Medicine from March 2017 to January 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were atomization inhalation administered with Fluticasone Propionate Inhaled Aerosol, 2 presses/time, twice daily. Patients in the treatment group were po administered with Chuansouning Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary function indexes, EOS count, ECP levels, and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.00% and 92.00%, respectively, and there was difference between two groups (P<0.05). After treatment, FVC, FEV1, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes levels in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, EOS count and ECP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP and TNF-α in two groups were significantly decreased, but the levels of IL-10 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factor levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Chuansouning Tablets combined with Fluticasone Propionate Inhaled Aerosol has clinical curative effect in treatment of cough variant asthma, can improve pulmonary function, and reduce the serum level of inflammatory factors, which has a certain clinical application value.
[中图分类号]
R974;R985
[基金项目]